South Korea
South Korea

Time filter

Source Type

The present invention relates to a manufacturing method for softgel capsule containing solid and liquid formulations as core ingredient, wherein at least one pharmaceutical drug can be included in both solid formulation and liquid formulation. More particularly, this invention relates to a softgel capsule wherein liquid formulation, for example, solution and/or suspension as well as solid formulation, for example, tablet, pellet and/or sustained release dosage are present as core ingredient and its manufacturing method.


The present invention relates to a manufacturing method for softgel capsule containing solid and liquid formulations as core ingredient, wherein at least one pharmaceutical drug can be included in both solid formulation and liquid formulation. More particularly, this invention relates to a softgel capsule wherein liquid formulation, for example, solution and/or suspension as well as solid formulation, for example, tablet, pellet and/or sustained release dosage are present as core ingredient and its manufacturing method.


News Article | November 4, 2016
Site: www.newsmaker.com.au

Steady increase in the number of photochemically unstable drugs will continue to positively influence the growth of the empty capsules market in 2016, with global revenues expected to increase by 6% to reach US$ 1,432.6 Mn. Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers. Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016.  Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively. Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016. Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market. Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$ 940.8 Mn. Demand will also be healthy in the cosmetics and nutraceutical sector, with this segment collectively accounting for nearly US$ 360 Mn in revenues in 2016. The U.S. is the largest market for empty capsules, with total revenues expected to reach US$ 500 Mn in 2016. The North America empty capsules market (U.S. and Canada) is the largest globally in terms of revenues, accounting for nearly 43% revenue share of the market. Western Europe will maintain its position as the second largest market for empty capsules, with total revenues expected to reach US$ 279.4 Mn in 2016. Germany and France are the two largest markets in terms of revenues, with the former accounting for the highest revenue share and the latter growing at the highest rate. Key players in the global empty capsules market included include Capsugel, ACG Worldwide, CapsCanada Corporation, Roxlor LLC, Qualicaps, Inc., Suheung Co., Ltd., Medi-Caps Ltd., Sunil Healthcare Ltd., Snail Pharma Industry Co., Ltd. and Bright Pharma Caps, Inc. Long-term Outlook: The global empty capsules market is anticipated to increase at a CAGR of over 7% to reach US$ 2,902.5 Mn in revenues by 2026.


Yang J.H.,Suheung Co. | Han J.T.,Suheung Co. | Oh I.H.,Suheung Co. | Park G.D.,Suheung Co.
Journal of the Korean Society of Food Science and Nutrition | Year: 2015

We investigated the applicability of polyethylene glycol (PEG) as a plasticizer in enteric-coated soft capsules based on determination of quality characteristics according to molecular weight and concentration of enteric-coating PEG solution. There was no difference according to molecular weight of PEG, whereas a low PEG concentration in the enteric-coating solution was associated with higher whiteness index and slower disintegration time in pH 6.8 media. Brittleness was observed in the coating film at seam areas in 5% PEG enteric-coating solution after 2 weeks of storage at room temperature. The enteric-coating properties of PEG were compared with those of acetylated monoglyceride (AMG) and triacetin, which are enteric-coating plasticizers. Enteric-coated soft capsule containing PEG as a plasticizer showed a lower whiteness index and faster dissolution profile than AMG and triacetin. Moreover, enteric-coated soft capsule containing AMG and triacetin as plasticizers showed coating film brittleness at seam areas after 2 months of accelerated storage [40°C, relative humidity (RH) 75%] but no difference at room temperature storage (25°C, RH 60%). The present study suggests that concentration of PEG is important to determine enteric-coating quality, regardless of the molecular weight of PEG. In conclusion, PEG has potential as a plasticizer due to its transparency and storage stability in enteric-coated soft capsules. © 2015, Korean Society of Food Science and Nutrition. All rights reserved.

Loading Suheung Co. collaborators
Loading Suheung Co. collaborators